PFIZER Q1 FY26 earnings call PFE

Pfizer reported a strong Q1 FY26, exceeding revenue and adjusted EPS expectations with revenues of $14.5 billion and adjusted diluted EPS of $0.75. The company emphasized disciplined execution across strategic priorities, including managing costs and making targeted investments for future growth. Launched and acquired products were a key driver, delivering $3.1 billion in Q1 and growing 22% operationally, demonstrating the early impact of portfolio transition.

The company made significant R&D progress with three positive Phase III readouts and encouraging mid-stage results. Pfizer is on track for approximately 20 pivotal study starts, 8 key data readouts, and 4 regulatory decisions in 2026, focusing investments in oncology, metabolic disease, and vaccines. Roughly half of the anticipated key data readouts and regulatory decisions in 2026 are expected from oncology.

Oncology remains a core focus, with the Seagen acquisition transforming the organization and advancing its ADC platform, contributing 20% year-over-year operational revenue growth in Q1. PADCEV showed compelling EV-304 study findings, reducing the risk of recurrence or death by nearly 50% in cisplatin-eligible muscle invasive bladder cancer. ELREXFIO demonstrated significant improvement in progression-free survival for double-class exposed relapsed or refractory multiple myeloma patients in the Phase III MagnetisMM-5 study. The company is also advancing a potential first-in-class nDiKA4 inhibitor for HER-2 negative breast cancer.

The Metsera acquisition underpins Pfizer's strategy in the next generation of obesity treatments, with plans to advance 10 Phase III studies this year and target a first approval in 2028 for a portfolio including ultra-long active peptides. Nurtec, from the Biohaven acquisition, continued its strong performance with 41% operational growth in Q1, driven by robust demand in both acute and preventive migraine treatments, highlighting the company's commercial capabilities in the oral CGRP class.

Pfizer is expanding its pneumococcal conjugate vaccine leadership, initiating a Phase III program for a 25-valent pediatric candidate with increased balancing and next-generation serotype 3 technology. The company also announced plans to advance directly to a 35-valent adult vaccine candidate, expecting to enter clinical development this year. This strategy aims to maintain current market leadership in the adult market over the long term^⏳.

The company's capital allocation strategy focuses on reinvesting in the business, maintaining and growing the dividend, and preserving flexibility for future value-enhancing actions like share repurchases. Recent legal developments, including the VYNDAMAX settlement extending patent exclusivity and the COMIRNATY Belgium court ruling, enhance cash flow visibility and support long-term capital allocation priorities, including the ability to preserve and support the dividend.

Pfizer is embedding artificial intelligence across R&D, commercial, manufacturing, and core enterprise functions as a key strategic priority. Leveraging AI is central to its innovation strategy, aiming to compress timelines and improve decision-making in the discovery, development, and delivery of new medicines and vaccines by utilizing Pfizer's vast repository of translational and clinical data.